- Home
- Publications
- Publication Search
- Publication Details
Title
The Evolution of Adjuvant Therapy for Melanoma
Authors
Keywords
-
Journal
Current Oncology Reports
Volume 21, Issue 12, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-11-26
DOI
10.1007/s11912-019-0858-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2019
- (2019) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Single-center real-life experience with low-dose ipilimumab monotherapy in adjuvant setting for patients with stage III melanoma
- (2019) Joanna Mangana et al. MELANOMA RESEARCH
- What Is the Role of Dabrafenib Plus Trametinib Adjuvant Therapy in Stage IIIA Melanoma?
- (2019) Elif Hindié JOURNAL OF CLINICAL ONCOLOGY
- United States Intergroup E1609: A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon-α2b for resected high-risk melanoma.
- (2019) Ahmad A. Tarhini et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II single-arm multicenter study of adjuvant ipilimumab in combination with nivolumab in subjects with high-risk ocular melanoma.
- (2019) Suthee Rapisuwon et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial
- (2019) Alexander M.M. Eggermont et al. EUROPEAN JOURNAL OF CANCER
- Cost-effectiveness of dabrafenib and trametinib in combination as adjuvant treatment of BRAF V600E/K mutation-positive melanoma from a US healthcare payer perspective
- (2019) Margaret E. Gerbasi et al. JOURNAL OF MEDICAL ECONOMICS
- BrUOG 324: Adjuvant nivolumab and low-dose ipilimumab for stage IIC, III, and resected stage IV melanoma: A phase II Brown University Oncology Research Group trial.
- (2018) Maria Constantinou et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-Term Outcomes in Patients With BRAF V600–Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib
- (2018) Georgina V. Long et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant vemurafenib in resected, BRAF V600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
- (2018) Michele Maio et al. LANCET ONCOLOGY
- Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
- (2018) Alexander M.M. Eggermont et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dabrafenib plus trametinib (D + T) as adjuvant treatment of resected BRAF-mutant stage III melanoma: Findings from the COMBI-AD trial analyzed based on AJCC 8 classification.
- (2018) James M. G. Larkin et al. JOURNAL OF CLINICAL ONCOLOGY
- Assessing the value of nivolumab (NIVO) versus placebo (PBO) and ipilimumab (IPI) as adjuvant therapy for resected melanoma.
- (2018) Morganna Louise Freeman et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect on health-related quality of life (HRQOL) of adjuvant treatment (tx) with dabrafenib plus trametinib (D + T) in patients (pts) with resected stage III BRAF-mutant melanoma.
- (2018) Dirk Schadendorf et al. JOURNAL OF CLINICAL ONCOLOGY
- Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600–Mutant Stage III Melanoma
- (2018) Axel Hauschild et al. JOURNAL OF CLINICAL ONCOLOGY
- Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial
- (2017) Corneel Coens et al. LANCET ONCOLOGY
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
- (2017) Jeffrey Weber et al. NEW ENGLAND JOURNAL OF MEDICINE
- Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma
- (2017) Mark B. Faries et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
- (2017) Georgina V. Long et al. NEW ENGLAND JOURNAL OF MEDICINE
- Predictors of responses to immune checkpoint blockade in advanced melanoma
- (2017) N. Jacquelot et al. Nature Communications
- Four-month course of adjuvant dabrafenib in patients with surgically resected stage IIIC melanoma characterized by a BRAFV600E/K mutation
- (2017) Parisa Momtaz et al. Oncotarget
- Adjuvant Ipilimumab for Melanoma—The $1.8 Million per Patient Regimen
- (2017) Daniel A. Goldstein JAMA Oncology
- Melanoma
- (2017) Daniel G. Coit et al. Journal of the National Comprehensive Cancer Network
- Immunophenotyping of Stage III Melanoma Reveals Parameters Associated with Patient Prognosis
- (2016) Nicolas Jacquelot et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
- (2016) Alexander M.M. Eggermont et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor associated PD-L1 expression pattern in microscopically tumor positive sentinel lymph nodes in patients with melanoma
- (2015) Ahmad A. Tarhini et al. Journal of Translational Medicine
- Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
- (2015) Alexander M M Eggermont et al. LANCET ONCOLOGY
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Adaptive Immune Resistance: How Cancer Protects from Immune Attack
- (2015) A. Ribas Cancer Discovery
- Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study
- (2014) Pippa G Corrie et al. LANCET ONCOLOGY
- Long-Term Results of the Randomized Phase III Trial EORTC 18991 of Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma
- (2012) Alexander M.M. Eggermont et al. JOURNAL OF CLINICAL ONCOLOGY
- Multivariate Analysis of Prognostic Factors Among 2,313 Patients With Stage III Melanoma: Comparison of Nodal Micrometastases Versus Macrometastases
- (2010) Charles M. Balch et al. JOURNAL OF CLINICAL ONCOLOGY
- Interferon Alpha Adjuvant Therapy in Patients With High-Risk Melanoma: A Systematic Review and Meta-analysis
- (2010) S. Mocellin et al. JNCI-Journal of the National Cancer Institute
- Randomized Phase III Study of 1 Month Versus 1 Year of Adjuvant High-Dose Interferon Alfa-2b in Patients With Resected High-Risk Melanoma
- (2009) Dimitrios Pectasides et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started